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Lactic acidosis is commonly observed in clinical situations such as shock and sepsis, as a result of tissue hypoperfusion and hypoxia.
Lymphoma and leukemia are among other clinical situations where lactic acidosis has been reported. We present a case of a 59year-old female with lactic acidosis who was found to have aggressive B-cell lymphoma. There have been 29 cases of lymphoma
induced lactic acidosis reported thus far; however all reported cases have abnormal vital signs or concomitant medical conditions
that may lead to lactic acidosis. The pathogenesis of malignancy-induced lactic acidosis is not well understood; however associated
factors include increased glycolysis, increased lactate production by cancer cells, and decreased hepatic clearance of lactate. When
it occurs, lactic acidosis is a poor prognostic sign in these patients. Prompt diagnosis and treatment of underlying lymphoma or
leukemia remains the only way to achieve complete resolution of lactic acidosis in these patients.
Copyright © 2009 Farn Huei Chan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.

1. Introduction
Lactic acidosis is a common cause of an anion gap acidosis
that often carries a significant risk for mortality. Lactic
acidosis most commonly results from an imbalance between
oxygen delivery and oxygen demand (Type A). However,
it can also occur in the absence of a recognizable impairment in systemic oxygen delivery, resulting from impaired
oxidative phosphorylation (Type B). Type B lactic acidosis
is associated with numerous conditions, including inborn
errors of metabolism, drugs and toxins, systemic diseases
(i.e., diabetes and sepsis), and less commonly, malignancy.
Lactic acidosis has been reported in cases of lymphoma
and leukemia. The exact pathophysiology and the best way
to manage lactic acidosis in this setting remain unclear. We
present a case and review the literature relating to lactic
acidosis in lymphoma.

2. Case Report
A previously healthy 59-year-old high school teacher presented with severe fatigue, generalized weakness, decreased

appetite, weight loss, and increased abdominal swelling for
2 months. She reported no fever, night sweats, cough, or
urinary symptoms. On physical examination, she appeared
cachectic with temporal muscle wasting. Blood pressure was
113/38, heart rate was 134/min, respiratory rate was 22/min,
temperature was 98.6◦ F, and she was not hypoxic on room
air. The spleen tip was palpated at 10 cm below the left costal
margin. Physical exam findings were otherwise normal.
Laboratory data revealed sodium 134 mmol/L, potassium 4.4 mmol/L, chloride 93 mmol/L, carbon dioxide
<10 mmol/L, anion gap >31 , blood urea nitrogen (BUN)
25 mg/dL, creatinine 0.6 mg/dL, and glucose 87 mg/dL.
Other pertinent labs included leukocyte count 6.4 × 109 /L,
hemoglobin 4.1 g/dL, platelet count 19 × 109 /L, aspartate
transaminase (AST) 103 U/L, alanine transaminase (ALT)
15 U/L, alkaline phosphatase 104 U/L, lactate dehydrogenase (LDH) 647 mmol/L (normal range 0.5–2.2 mmol/L),
haptoglobin 55 mg/dL, uric acid 13.6 mg/dL, and lactate
16.5 mmol/L. Arterial blood gas revealed a pH of 7.33, a
PCO2 of 21 mmHg, and PO2 of 132 mmHg, with a bicarbonate of 11.2 mmol/L. Peripheral blood smear revealed no blast
cells or abnormal leukocytes. Blood cultures were negative.
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Figure 3: Correlation between lactate level, pH, bicarbonate,
creatinine, and hemoglobin.
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Figure 1: Computed tomography scan of the abdomen showed
massive splenomegaly and extensive lymphadenopathy . (L: liver, S:
spleen, N: lymphadenopathy).
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Figure 2: Correlation between lactate level and vital signs.

Computed tomography (CT) scan of the abdomen and pelvis
revealed massive splenomegaly measuring 25 cm craniocaudally, and extensive lymphadenopathy in the abdomen and
pelvis (Figure 1).
The patient was aggressively hydrated and received blood
transfusions to improve her anemia. However, she remained
tachycardic. Throughout her hospital course, her blood
pressures remained stable. No source of infection or bleeding
was identified. With these measures, lactate improved to
6.7 mmol/L but shortly after that rose to 27.7 mmol/L
(Figures 2 and 3).
While awaiting pathological diagnosis, the patient deteriorated clinically, and on day 4, intravenous corticosteroids
were administered for presumed high-grade lymphoma. In
addition, a sodium bicarbonate infusion and allopurinol
were initiated for tumor lysis syndrome prophylaxis.

Bone marrow biopsy revealed a diﬀuse (>50%) infiltrate
of cells positive for CD 45 and CD 20, negative for CD 5,
CD 10, CD 23, and cyclin D1. GTG-banding studies reveal a
very complex karyotype. However, morphologically the cells
were not large enough to be called large B-cell lymphoma.
The final diagnosis was CD 20-positive B-cell lymphoma.
Cyclophosphamide, vincristine, and prednisone were started
on day 7. On day 8, she developed respiratory distress
with new bilateral pulmonary infiltrates concerning for
adult respiratory distress syndrome and became hypotensive
requiring vasopressor support. Given the severity of the
multiple organ failure, her family decided to withdraw
support, and she died on hospital day 12. Autopsy revealed
extensive lymphoma as well as diﬀuse pulmonary, kidney,
and esophageal hemorrhage.

3. Discussion
Lactate is produced from the anaerobic metabolism of
pyruvate, which in turn is generated from glucose via glycolysis. Therefore, lactate production is a surrogate marker
of acidosis during a hypoxic state, and not the direct cause.
Lactic acidosis is infrequently encountered in malignancies;
yet when present portends an extremely poor prognosis [1].
Moreover, the strikingly high mortality associated with lactic
acidosis has prompted some oncologists to consider this
an oncological emergency [2]. Hematologic malignancies,
including acute leukemias and high-grade lymphomas, are
the most common neoplastic disorders associated with lactic
acidosis. Twenty nine cases of lymphoma induced lactic
acidosis have been published in English language journals
(Table 1). Seven patients experienced either a partial or
complete remission, three of whom subsequently expired
from recurrence and there is no long-term followup on an
additional two patients. As patients with malignancy induced
lactic acidosis are often criticallyill, it is diﬃcult to discern
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Table 1: Summary of all reported cases of lactic acidosis associated with lymphoma. (NR: normal range; BP: blood pressure; RR: respiratory
rate; P: pulse; T: temperature.)
Reference

Age

Type of
lymphoma

Lactate
(mmol/L)

Vitals

Directed treatment
of lactic acidosis

Chemo

Outcome

Friedenberg
et al. [3]

75

Follicular

5.4

BP NR P104

None

Yes

Died in 2
days

Friedenberg
et al. [3]

54

T-cell

12

BP 120/50 P 92

None

Yes

Died in 10
weeks

Friedenberg
et al. [3]

54

Diﬀuse large
B-cell

18

BP 96/40 P118

Hemodialysis

Yes

Died in 4
days

Concomitant
sepsis (presumed)

He et al. [4]

28

Natural
Killer/T-cell

11.2

NR

IV Bicarbonate

Yes

Remission

Died from
recurrence after
undisclosed
period of time

Prikis et al.
[5]

65

Large B-cell

18

NR

IV bicarbonate and
dialysis

Yes

Remission

Sustained low
eﬃciency dialysis

Large B-cell

33.0

BP 100/60 P 95 IV Bicarbonate and
RR18 T 36.7 C
Hemodialysis

Yes

Burkitt’s

15.8

NR

None

No

Mantle Cell

26.3

NR

IV Bicarbonate

Yes

Remission

Large B-cell

9.0

NR

IV Bicarbonate

Yes

Died

Dogan et al.
24
[6]
Glasheen and
74
Sorensen [7]
Ohtsubo
77
et al. [8]
DiComite
et al. [9]

64

Sillos et al.
[1]

18

Thakur et al.
82
[10]
Yasin and
Hartranft
[11]
Durig et al.
[12]
ScheuleerHolmes et al.
[13]
Caspar and
Oelz [14]
Caspar and
Oelz [14]
Caspar and
Oelz [14]
Doolittle
et al. [15]

Comments

Died within
10 days
Died in 13
days

Large T-cell

15.4

NR

IV bicarbonate

Yes

Remission

Hodgkin’s

11.5

NR

IV bicarbonate

No

Died in 3
days

Unclear time to
death
Lymphoma
recurred and died
in 7 months

Presumed
ascending
cholangitis. Had
two exploratory
operations

76

Large B-cell

13.1

NR

None

No

Died in 7
days

71

NonHodgkin’s

17.4

BP 120/60 P120

IV Bicarbonate

Yes

Died in 14
days

54

NonHodgkin’s

16.4

BP 160/90 P 92
RR 26 T 37.1 C

IV Bicarbonate

Yes

Died within 3
months

14.8

NR

None

No

Died in 2
days

12.2

BP 165/100 P
100

IV Bicarbonate

Yes

Remission

Died in 6 months

74
71

NonHodgkin’s
NonHodgkin’s

34

NonHodgkin’s

23.6

NR

IV Bicarbonate

Yes

Remission

Lactic acidosis
occurred after
exploratory
operation

19

Diﬀuse
Histiocytic

21.8

BP 90/60 P 120
RR 24, Temp
101 F

IV Bicarbonate

Yes

Died in 5
weeks

Blood cultures
negative

Hodgkin’s

16.3

NR

IV Bicarbonate

Yes

Died in 24
days

NonHodgkin’s

32

NR

None

Yes

Remission

Doolittle
60
et al. [15]
Vandermolen
32
et al. [16]
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Table 1: Continued.

Reference

Age

Type of
lymphoma

Johnson and
21 Non-Hodgkin’s
Whelan [17]
Leyden et al.
47
Hodgkin’s
[18]
Leyden et al.
61 Non-Hodgkin’s
[18]
Nadiminti
et al. [19]
Mintz et al.
[20]
Mintz et al.
[20]
Mintz et al.
[20]
Mintz et al.
[20]
Scheerer et al.
[21]

Lactate
(mmol/L)

Vitals

Directed treatment
of lactic acidosis

Chemo

16.1

NR

IV Bicarbonate

Yes

20.0

NR

IV Bicarbonate

Yes

46.8

NR

IV Bicarbonate

Yes

BP 120/80 P106

IV bicarbonate

Yes

IV Bicarbonate

No

IV Bicarbonate

Yes

None

Yes

None

Yes

IV bicarbonate

Yes

30

Hodgkin’s

14

65

Histiocytic

21.8

34

Histiocytic

14.2

60

Histiocytic

5.9

58

Histiocytic

4.5

47

Hodgkin’s

8.8

BP 114/66 P 124
RR 32
BP 120/75 P100
T 39C
BP 100/65 P 124
RR 30
BP 90/60 P 112
RR 50 T 39C
BP 112/80 P110

whether the etiology of lactic acidosis is completely a result
from the malignancy and not from other potential causes
of Type A lactic acidosis (i.e., sepsis, hypotension, hypoxia,
etc.). In the patient we present above, she did not have
hypoxia or significant hypotension when the lactic acidosis
was discovered. The lactic acidosis persisted despite volume
repletion, including blood transfusions. Furthermore, we
could not identify a source of infection and her lactic acidosis
preceded her intensive care visit. However, she was anemic,
tachycardic, and tachypneic at presentation. Therefore, it is
impossible to conclude there were no additional influences
that may have led to Type A lactic acidosis. Upon reviewing
the current literature of lymphoma induced lactic acidosis,
many cases did have concomitant sepsis, anemia, surgical
procedures, or abnormal vital signs (Table 1). Accordingly,
every published case that reported vital signs had at least
one vital sign indicative of systemic inflammatory response.
As the majority of cases to date had concomitant factors
that potentially could lead to lactic acidosis, as in the case
we present above, the true incidence of lymphoma induced
lactic acidosis remains cloudy.
The pathogenesis of lactic acidosis in lymphoma is
incompletely understood and likely multifactorial. Liver
metastasis and dysfunction is often cited as a potential
cause because of reduced hepatic utilization of lactate via
gluconeogenesis [7]. However, lactic acidosis can occur in the
absence of liver dysfunction [1, 22, 23]. In fact, Sillos et al.
reported 19% of patients with lactic acidosis in the setting of
hematological malignancies did not have liver involvement
[1]. Furthermore, lactic acidosis is uncommon in patients
with cirrhosis or fulminant hepatic failure in the absence
of malignancy [24]. Accordingly, although liver dysfunction
may contribute to the development of lactic acidosis, it is

Outcome

Comments

Died in 14 WBC 27,700 and
days
presumed sepsis
Died within 6
Pneumonia
days
Gastrointestinal
Died in one hemorrhage with
day
hemoglobin of
4.0 g/dL
Died in 4
weeks
Died in 4
days
Died in 8
days
Died in 3
weeks
Died in 2
weeks
Died in 11
days

unlikely to be the sole cause. Another potential mechanism
for lactic acidosis is increased glycolytic activity, with a
subsequent increase in lactate acid generation, in cancer
cells. Further supporting this hypothesis, several cases have
been characterized by recurrent hypoglycemia, presumably
related to increased glycolysis [7, 9, 12]. Overexpression
of type II hexokinase [25], a glycolytic enzyme found in
mitochondria, or increased IGF-binding protein (IGFBP)
activity, has been implicated in the increased glycolysis in
cancer cells [1]. Finally, excessive lactate production may
result from highly aggressive tumors that simply outgrow
their blood supply [26]. In essence, there is production of
lactate from local hypoxia in the absence of any systemic
hypoxia or hypoperfusion.
Regardless of etiology, the treatment for lactic acidosis is
to discern and correct the underlying mechanism producing
the lactate, as well as to ensure adequate oxygen delivery
in cases of hypoxia. Accordingly, in malignancy derived
lactic acidosis, chemotherapy is the primary treatment
modality. As demonstrated in Table 1, the only treatment
modality that consistently leads to remission was initiation
of chemotherapy. Of the 29 reported cases of lymphoma
induced lactic acidosis, only seven went into remission, all
of whom received chemotherapy. Of the seven cases who
went into remission, the lactate levels normalized in 6 (one
case did not report what happened to the lactate levels after
chemotherapy). In five of the six cases, resolution of the
lactic acidosis occurred as early as 15 hours and up to 3
days after starting chemotherapy. In the remaining case,
the lactate level normalized weeks after chemotherapy was
introduced; however, did so within 2 days of starting salvage
chemotherapy. Thus, it is probably safe to conclude that
if lactic acidosis improves after chemotherapy, it occurs in
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timely manner. Additionally, it is conceivable that prompt
resolution of lactic acidosis could be a surrogate marker of
inducing remission.
Both intravenous (IV) bicarbonate and hemodialysis
have been used to control the lactic acidosis until chemotherapy can treat the malignancy. The use of IV bicarbonate
as an interim treatment of profound acidosis (in either the
presence or absence of malignancy) remains a contentious
issue [27–30]. As severe acidosis can cause respiratory fatigue
and hemodynamic instability, intravenous bicarbonate is
often used to attenuate the sequelae of systemic acidosis.
However, there are potential side eﬀects from using IV
sodium bicarbonate. The most obvious of which are hypervolemia and hypernatremia [31]. Additionally, sodium bicarbonate infusion may actually increase lactic acid production
[28]. The rise in lactate levels has been seen in human
[32] and animal [33, 34] studies. The decreased oxygen
delivery has been postulated to occur from both a reduction
in PaO2 [35] as well as increased aﬃnity of oxygen to
hemoglobin resulting from the rise in systemic pH following
IV bicarbonate infusion [36]. The eﬀect of IV bicarbonate
on mortality or lactate concentrations in the setting of
malignancy induced lactic acidosis has not been directly
studied. From our review of the literature, 20 of the 29
cases used IV bicarbonate to treat the acidosis. Two patients
received IV bicarbonate without adjunctive chemotherapy,
and both died within days. Of the 7 patients who went
into remission, 6 were on IV bicarbonate. Although it
is unlikely that bicarbonate administration provides any
mortality benefit beyond chemotherapy, this has not been
directly studied.
Renal replacement therapy (RRT), including hemodialysis, peritoneal dialysis, or hemofiltration can be used
to remove lactate and correct acidosis [37]. Prikis et al.
recently reported a case of lymphoma induced lactic acidosis
successfully treated with sustained low eﬃciency dialysis
implemented as a temporary measure to correct acidosis
and hypervolemia until chemotherapy was initiated [5]. Two
other cases of lymphoma induced lactic acidosis have been
treated with hemodialysis and chemotherapy, both of whom
died within 10 days. As the prognosis of lymphoma induced
lactic acidosis is grim, the only hope for remission is starting
chemotherapy. Although IV bicarbonate and hemodialysis
can be implemented in an attempt to control the acidosis,
it must be emphasized that these measures should be viewed
as a bridge until the underlying cause is treated.
In conclusion, lactic acidosis is an ominous sign in
patients with lymphoma or leukemia. The exact pathogenesis
of this condition remains unclear. Prompt diagnosis and
early treatment of underlying lymphoma or leukemia is the
only way to achieve complete resolution of lactic acidosis in
these patients.

References
[1] E. M. Sillos, J. L. Shenep, G. A. Burghen, C.-H. Pui, F. G. Behm,
and J. T. Sandlund, “Lactic acidosis: a metabolic complication
of hematologic malignancies: case report and review of the
literature,” Cancer, vol. 92, no. 9, pp. 2237–2246, 2001.

5
[2] F. I. Jabr, “Lactic acidosis in patients with neoplasms: an
oncologic emergency,” Mayo Clinic Proceedings, vol. 81, no. 11,
pp. 1505–1506, 2006.
[3] A. S. Friedenberg, D. E. Brandoﬀ, and F. J. Schiﬀman,
“Type B lactic acidosis as a severe metabolic complication in
lymphoma and leukemia: a case series from a single institution
and literature review,” Medicine, vol. 86, no. 4, pp. 225–232,
2007.
[4] Y.-F. He, W. Wei, Z.-M. Sun, et al., “Fatal lactic acidosis and
hypoglycemia in a patient with relapsed natural killer/T-cell
lymphoma,” Advances in Therapy, vol. 24, no. 3, pp. 505–509,
2007.
[5] M. Prikis, V. Bhasin, M. P. Young, F. J. Gennari, and J.
M. Rimmer, “Sustained low-eﬃciency dialysis as a treatment
modality in a patient with lymphoma-associated lactic acidosis,” Nephrology Dialysis Transplantation, vol. 22, no. 8, pp.
2383–2385, 2007.
[6] E. Dogan, R. Erkoc, H. Sayarlioglu, S. Alici, I. Dilek, and O.
Alici, “Fatal lactic acidosis due to leukemic transformation in a
patient with non-Hodgkin’s lymphoma: case report,” Advances
in Therapy, vol. 22, no. 5, pp. 443–446, 2005.
[7] J. J. Glasheen and M. D. Sorensen, “Burkitt’s lymphoma
presenting with lactic acidosis and hypoglycemia—a case
presentation,” Leukemia and Lymphoma, vol. 46, no. 2, pp.
281–283, 2005.
[8] K. Ohtsubo, R. Imamura, R. Seki, et al., “Blastoid variant
of mantle cell lymphoma with lactic acidosis: a case report,”
International Journal of Hematology, vol. 80, no. 5, pp. 428–
431, 2004.
[9] G. Di Comite, L. Dagna, P. M. Piatti, L. D. Monti, F. Tantardini,
and L. Praderio, “Hypoglycaemia and lactic acidosis in a
MALT non Hodgkin’s lymphoma,” Leukemia and Lymphoma,
vol. 43, no. 6, pp. 1341–1342, 2002.
[10] V. Thakur, G. Sander, and S. T. Rab, “Hodgkin’s disease and
lactic acidosis,” Nephron, vol. 88, no. 3, pp. 276–277, 2001.
[11] M. Yasin and T. H. Hartranft, “Primary hepatic lymphoma:
unusual presentation and clinical course,” American Surgeon,
vol. 63, no. 11, pp. 951–953, 1997.
[12] J. Dürig, W. Fiedler, M. De Wit, M. Steﬀen, and D. K. Hossfeld,
“Lactic acidosis and hypoglycemia in a patient with highgrade non-Hodgkin’s lymphoma and elevated circulating
TNF-α,” Annals of Hematology, vol. 72, no. 2, pp. 97–99, 1996.
[13] M. L. Scheurleer-Hommes, M. R. Schaafsma, and J. C. KluinNelemans, “Lactic acidosis in a patient with B-cell nonHodgkin’s lymphoma,” Leukemia, vol. 8, no. 6, pp. 1065–1066,
1994.
[14] C. B. Caspar and O. Oelz, “Lactic acidosis in malignant
lymphoma,” American Journal of Medicine, vol. 91, no. 2, pp.
197–198, 1991.
[15] G. C. Doolittle, M. W. Wurster, C. S. Rosenfeld, and D. C.
Bodensteiner, “Malignancy-induced lactic acidosis,” Southern
Medical Journal, vol. 81, no. 4, pp. 533–536, 1988.
[16] L. A. VanderMolen, S. Swain, and D. L. Longo, “Lactic acidosis
in lymphoma: prompt resolution with therapy directed at
lymphoma,” Journal of the National Cancer Institute, vol. 80,
no. 13, pp. 1077–1078, 1988.
[17] D. A. Johnson and T. V. Whelan, “Lactic acidosis—a review
of the association with neoplastic disorder,” Military Medicine,
vol. 150, no. 4, pp. 206–208, 1985.
[18] M. Leyden, J. Sullivan, J. Szer, and G. Brodie, “Fatal lactic
acidosis in lymphoma. A report of two cases,” Australian and
New Zealand Journal of Medicine, vol. 13, no. 2, pp. 179–180,
1983.

6
[19] Y. Nadiminti, J. C. Wang, and S.-Y. Chou, “Lactic acidosis associated with Hodgkin’s disease. Response to chemotherapy,”
The New England Journal of Medicine, vol. 303, no. 1, pp. 15–
17, 1980.
[20] U. Mintz, D. L. Sweet Jr., J. D. Bitran, and J. E. Ultmann,
“Lactic acidosis and diﬀuse histiocytic lymphoma (DHL),”
American Journal of Hematology, vol. 4, no. 4, pp. 359–365,
1978.
[21] P. P. Scheerer, R. V. Pierre, D. L. Schwartz, et al., “ReedSternberg-Cell leukemia and lactic acidosis; unusual manifestations of Hodgkin’s disease,” The New England Journal of
Medicine, vol. 270, pp. 274–278, 1964.
[22] K. S. Rao, R. Mehta, and J. Ferlinz, “Unusual presentation of
cancer-induced lactic acidosis,” Postgraduate Medical Journal,
vol. 64, no. 752, p. 475, 1988.
[23] M. Fujimura, H. Shirasaki, K. Kasahara, and T. Matsuda,
“Small cell lung cancer accompanied by lactic acidosis and
syndrome of inappropriate secretion of antidiuretic hormone,” Lung Cancer, vol. 22, no. 3, pp. 251–254, 1998.
[24] C. O. Record, R. A. Iles, R. D. Cohen, and R. Williams, “Acid
base and metabolic disturbances in fulminant hepatic failure,”
Gut, vol. 16, no. 2, pp. 144–149, 1975.
[25] S. Mazurek, C. B. Boschek, and E. Eigenbrodt, “The role of
phosphometabolites in cell proliferation, energy metabolism,
and tumor therapy,” Journal of Bioenergetics and Biomembranes, vol. 29, no. 4, pp. 315–330, 1997.
[26] S. Archer and B. Bache-Wiig, “Lactic acidosis B associated with
solid tumors,” Minnesota Medicine, vol. 69, no. 9, pp. 511–514,
1986.
[27] D. Mathieu, R. Neviere, V. Billard, M. Fleyfel, and F. Wattel,
“Eﬀects of bicarbonate therapy on hemodynamics and tissue
oxygenation in patients with lactic acidosis: a prospective,
controlled clinical study,” Critical Care Medicine, vol. 19, no.
11, pp. 1352–1356, 1991.
[28] S. M. Forsythe and G. A. Schmidt, “Sodium bicarbonate for
the treatment of lactic acidosis,” Chest, vol. 117, no. 1, pp. 260–
267, 2000.
[29] B. Cuhaci, J. Lee, Z. Ahmed, S. M. Forsythe, and G. A. Schmidt,
“Sodium bicarbonate controversy in lactic acidosis,” Chest,
vol. 118, no. 3, pp. 882–884, 2000.
[30] M. L. Halperin, S. Cheema-Dhadli, F. A. Halperin, and K.
S. Kamel, “Rationale for the use of sodium bicarbonate in
a patient with lactic acidosis due to a poor cardiac output,”
Nephron, vol. 66, no. 3, pp. 258–261, 1994.
[31] J. A. Mattar, M. H. Weil, H. Shubin, and L. Stein, “Cardiac
arrest in the critically ill—part II: hyperosmolal states following cardiac arrest,” American Journal of Medicine, vol. 56, no.
2, pp. 162–168, 1974.
[32] A. L. A. Fields, S. L. Wolman, and M. L. Halperin, “Chronic
lactic acidosis in a patient with cancer: therapy and metabolic
consequences,” Cancer, vol. 47, no. 8, pp. 2026–2029, 1981.
[33] H. Graf, W. Leach, and A. I. Arieﬀ, “Metabolic eﬀects of
sodium bicarbonate in hypoxic lactic acidosis in dogs,” The
American Journal of Physiology, vol. 249, no. 5, part 2, pp.
F630–635, 1985.
[34] K. H. Rhee, L. O. Toro, G. G. McDonald, R. L. Nunnally,
and D. L. Levin, “Carbicarb, sodium bicarbonate, and sodium
chloride in hypoxic lactic acidosis: eﬀect on arterial blood
gases, lactate concentrations, hemodynamic variables, and
myocardial intracellular pH,” Chest, vol. 104, no. 3, pp. 913–
918, 1993.
[35] R. M. Bersin, K. Chatterjee, and A. I. Arieﬀ, “Metabolic and
hemodynamic consequences of sodium bicarbonate administration in patients with heart disease,” American Journal of
Medicine, vol. 87, no. 1, pp. 7–14, 1989.

Case Reports in Medicine
[36] A. J. Bellingham, J. C. Detter, and C. Lenfant, “Regulatory
mechanisms of hemoglobin oxygen aﬃnity in acidosis and
alkalosis,” Journal of Clinical Investigation, vol. 50, no. 3, pp.
700–706, 1971.
[37] P. J. Fall and H. M. Szerlip, “Lactic acidosis: from sour milk to
septic shock,” Journal of Intensive Care Medicine, vol. 20, no. 5,
pp. 255–271, 2005.

MEDIATORS
of

INFLAMMATION

The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Gastroenterology
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Hindawi Publishing Corporation
http://www.hindawi.com

Diabetes Research
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

International Journal of

Journal of

Endocrinology

Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com

Disease Markers

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Submit your manuscripts at
http://www.hindawi.com
BioMed
Research International

PPAR Research
Hindawi Publishing Corporation
http://www.hindawi.com

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Volume 2014

Journal of

Obesity

Journal of

Ophthalmology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Evidence-Based
Complementary and
Alternative Medicine

Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Journal of

Oncology
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Parkinson’s
Disease

Computational and
Mathematical Methods
in Medicine
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

AIDS

Behavioural
Neurology
Hindawi Publishing Corporation
http://www.hindawi.com

Research and Treatment
Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

Oxidative Medicine and
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com

Volume 2014

